Schedule III and Cannabis Prices: What Actually Changes

September 26, 2026

Photo by Tom Tillhub via Pexels.

Scroll through the coverage from last spring and you'd think somebody flipped a switch and cannabis got cheaper overnight. It didn't, and it's not going to work that way. The headlines conflated two very different things: a change in how a business gets taxed, and a change in what a customer pays at the register. Those are not the same event, they don't happen on the same timeline, and conflating them is the single biggest source of confusion floating around this story right now.

Here's where things actually stand as of September 26, 2026. The reclassification that took effect is partial, not total. State-licensed medical marijuana product and FDA-approved cannabis drug products moved from Schedule I to Schedule III, with the rule taking effect upon Federal Register publication on April 28, 2026 (the DOJ order itself was dated April 23). Adult-use, recreational-market product -- the stuff most cannabis consumers in this country actually buy -- is still sitting in Schedule I, untouched. That distinction is the whole story, and it's the one that keeps getting flattened in casual coverage.

The real mechanism worth understanding isn't supply, demand, or federal legalization creeping closer. It's Section 280E of the tax code, and what happens to a company's bottom line when that provision no longer applies to it. Tax relief for operators and price relief for consumers are related, but they're not interchangeable, and this piece is going to keep returning to that gap -- because that gap is where most of the near-term uncertainty in this market actually lives.

The Rule That Actually Changed on April 23, 2026

Photo by David Dibert via Pexels.

Start with what the rule actually says, because the plain text matters more than the press release framing. The Department of Justice's final rule placed marijuana meeting two specific descriptions into Schedule III: product cultivated, processed, and sold under a state-licensed medical marijuana program, and cannabis-derived drug products that have gone through FDA approval (think Epidiolex-style pharmaceutical products, not dispensary flower). The rule became effective April 28, 2026, upon Federal Register publication, following DOJ's April 23 order. Everything outside those two categories -- which is to say, the overwhelming majority of product sold in adult-use recreational markets across the country -- remains Schedule I as a matter of federal law. Nothing about how that product is grown, packaged, taxed, or sold has changed federally.

That's not the end of the process, just the part that's finished. A separate DEA administrative hearing examining whether to reschedule marijuana more broadly ran from June 29 through July 15, 2026. Transcripts from that proceeding are now final, and the case sits with an administrative law judge awaiting a recommendation. No final rule has come out of it, and there's no fixed date by which one has to. The ALJ's recommendation isn't binding on DEA either way -- it's advisory, which is how these proceedings have historically worked -- so even a favorable recommendation doesn't guarantee a broader rescheduling order follows quickly, or at all.

Litigation is running in parallel. On September 9, 2026, the D.C. Circuit declined to block the medical rescheduling order, leaving it in effect over objections from parties trying to halt it. That's a win for the rule as it exists today, but it's not a final resolution -- the underlying litigation continues, and appellate outcomes in drug scheduling cases have a track record of taking years to fully settle.

Then there's the political layer sitting on top of the legal one. The House-passed version of the 2026 spending bill includes language barring the use of federal funds for further rescheduling action. If that rider survives conference and becomes law, it would effectively freeze DEA's ability to act on a favorable ALJ recommendation, regardless of what the administrative record supports. That combination -- an unresolved legal process plus a live funding restriction -- is why anyone predicting a firm date for full rescheduling right now is guessing, not reporting.

Why 280E Is the Real Price Lever, Not Scheduling Itself

Photo by Tara Winstead via Pexels.

Section 280E has nothing to do with cannabis policy in its origin. Congress enacted it in 1982, in direct response to a Tax Court case that let a convicted cocaine and amphetamine trafficker deduct ordinary business expenses -- yes, that's a real case, and it's the reason the provision exists. The rule Congress wrote bars any business trafficking in a Schedule I or Schedule II controlled substance from deducting the ordinary costs of running a business: rent, payroll, marketing, insurance, the works. It was never written with state-legal cannabis retailers in mind, because state-legal cannabis retail didn't exist in 1982. Once medical and then adult-use markets emerged decades later, 280E came along for the ride, and it has been the industry's single most punishing federal tax problem ever since.

The practical effect is stark. Because a cannabis retailer can't deduct most of what it costs to operate, its taxable income ends up bearing almost no relationship to its actual profit. Industry estimates have put effective federal tax rates on cannabis operators as high as 70 to 80 percent, compared to roughly 21 to 30 percent for an ordinary company in a comparable retail or manufacturing business. That's not a rounding-error disadvantage -- it's the difference between a business that can reinvest and one that's perpetually cash-starved even when it's selling product briskly.

Moving marijuana out of Schedule I and Schedule II removes it from 280E's scope entirely. For businesses that qualify under the new rule -- state-licensed medical operators and FDA-approved drug product makers -- ordinary operating expenses become deductible again, and taxable income starts looking like taxable income for any other company. Industry estimates put the aggregate national tax savings from this shift at around $2.3 billion annually if applied broadly across the affected segment. Maryland offers a concrete, store-level illustration: high-volume retailers there have been estimated to save an average of roughly $805,000 per store per year once 280E no longer applies to their medical operations.

The catch, and it's the catch this whole piece hangs on, is scope. That savings currently applies only to state-licensed medical operators and FDA-approved drug products. Adult-use retailers -- the segment doing the bulk of national cannabis sales volume -- are still fully subject to 280E. A dispensary selling both medical and adult-use product under one roof may find itself doing separate tax accounting for two lines of the same business, one newly relieved of 280E and one still trapped under it.

From Tax Savings to Shelf Price: A Chain With Several Weak Links

Rescheduling cannabis to Schedule III would slash the effective federal tax rate for medical cannabis operators from about 75% under current Schedule I/II 280E restrictions to roughly 25%, as businesses regain the ability to deduct normal operating expenses.

Here's the part that gets skipped in the excited coverage: a tax break improves a company's margin, but it does not obligate that company to lower its prices. Nothing in the tax code, or in the rescheduling order, requires an operator to pass a single dollar of 280E relief through to a customer. A newly-profitable medical operator can use that money to pay down high-interest debt taken on during years of cash-flow strain, raise wages to retain staff in a competitive labor market, open new retail locations, or simply improve its margin and keep the difference. All of those are rational, defensible business decisions, and none of them touch the shelf price.

Whether savings actually reach the consumer comes down to competitive dynamics in each state market, not federal tax law. In states with a large number of licensed operators competing hard for the same customers, competition tends to force some pass-through -- nobody wants to leave money on the table for a rival to undercut them with. In states running constrained-license systems, where a handful of operators hold most of the market and new licenses are capped or unavailable, there's much less competitive pressure to pass anything through, and margin tends to stay put. This isn't a cannabis-specific phenomenon -- it's the general pattern seen whenever a cost-side regulatory change hits a retail sector: pass-through happens fastest where supply is genuinely competitive, and slowest or not at all where market structure lets incumbents hold price.

Complicating the picture further, cannabis retail was already in the middle of a serious price correction before any of this rescheduling news broke. Twenty-three states saw cannabis sales declines in 2025, and the industry broadly has been contending with oversupply and active price wars in mature markets like California, Oregon, and Colorado for reasons that have nothing to do with federal tax classification. Cultivation capacity in several states has simply outrun consumer demand, and that alone has been pushing wholesale and retail prices down independent of any 280E relief.

That overlap creates a real measurement problem. If shelf prices in a given medical market fall over the next year or two, sorting out how much of that decline reflects 280E-driven margin relief being passed through versus how much reflects plain oversupply and competitive price-cutting is going to be genuinely difficult. Anyone claiming a clean causal read on that question in the near term should be treated with some skepticism -- the data won't easily separate the two effects.

What Schedule III Doesn't Touch: Banking, Adult-Use Legality, and State Rules

Photo by 2427999 via Pixabay.

It's worth being explicit about everything Schedule III leaves untouched, because the list is longer than the list of things it changes. Marijuana in Schedule III is still a federally controlled substance. It is not legal in the sense that alcohol or an over-the-counter drug is legal. That distinction matters enormously for banking, because federally chartered banks and credit unions still carry real compliance exposure servicing cannabis businesses, medical or otherwise. Schedule III doesn't erase that exposure -- it just moves the drug to a different tier of the same controlled-substances framework. The cash-heavy, high-fee, limited-access banking structure that has defined cannabis retail for over a decade doesn't automatically change because of this rule.

The legislative fix that's supposed to address banking specifically -- the SAFE Banking Act, later reintroduced in expanded form as SAFER Banking -- has been proposed repeatedly in Congress for years and still hasn't been enacted into law. Rescheduling does not substitute for it, and there's no legal mechanism by which Schedule III status automatically triggers the banking access that SAFE/SAFER would provide. Those are separate legislative tracks that happen to both live under the broader cannabis-reform umbrella, and one moving doesn't pull the other along with it.

Just as important: rescheduling creates no federal legal pathway for recreational adult-use sales, full stop. State licensing regimes, packaging and labeling requirements, testing protocols, and state-level tax structures are entirely untouched by this rule. A consumer buying from an adult-use dispensary in a state with no medical carve-on that reaches Schedule III status sees literally zero direct pricing mechanism change as a result of this reclassification. Not eventually, not indirectly through some downstream effect -- there's simply no channel connecting the April 2026 rule to that consumer's receipt.

The practical upshot is a genuinely two-tier market, and it's a two-tier structure built into the rule by design, not an accident of implementation. State medical programs -- where they exist and where the operator is properly licensed -- get the 280E tax break. Adult-use programs, even when operating in the same state, under the same roof, sometimes sold by the same budtender, do not. That split can persist indefinitely under current law, and understanding it is the key to reading any pricing claim tied to rescheduling with appropriate skepticism.

The IRS Is Fighting the Retroactivity Question

Photo by stevepb via Pixabay.

A less-covered but consequential fight is happening inside federal tax courts right now, and it directly affects how much of the promised 280E relief operators actually get to keep. The rescheduling rule took effect April 28, 2026, and its tax consequences apply going forward from that date. But some cannabis operators, hoping to recover taxes paid under 280E's harsher treatment in prior years, have started filing amended returns attempting to apply Schedule III's more favorable tax treatment retroactively -- essentially arguing that if marijuana is Schedule III now, their 2023 or 2024 tax years should be recalculated as if it always had been.

The IRS, acting through the Department of Justice's Tax Litigation Branch, is actively challenging these retroactive claims in federal litigation. The government's position is straightforward and, frankly, unsurprising given how tax law usually treats reclassification events: 280E applied in full for any tax year in which marijuana was still classified as Schedule I or Schedule II, and the April 2026 reclassification doesn't rewrite the legal status of prior years. In the government's framing, the rule change is prospective, not a retroactive correction of past liability.

This matters for the price conversation because some operators have been counting on retroactive refunds as a source of capital -- money that could theoretically fund price cuts, retail expansion, or debt paydown beyond what forward-looking 280E relief alone would provide. If the IRS prevails in blocking retroactive claims, as its litigation posture suggests it intends to fight for, that anticipated windfall simply doesn't materialize. Some of the capital relief operators and investors modeled into their near-term projections could evaporate in court, leaving actual available cash meaningfully lower than the optimistic estimates floating around industry finance circles.

None of this is unprecedented, and precedent-watchers should recognize the pattern immediately: tax authorities have a long, consistent history of resisting retroactive application of favorable reclassifications, across industries well beyond cannabis. Betting on a retroactive tax windfall has historically been a weak assumption in comparable disputes, and there's no strong reason to expect cannabis operators will be the exception. Anyone modeling near-term price cuts on the assumption of retroactive refund capital is building on genuinely uncertain ground.

What to Actually Watch Over the Next 1-3 Years

Photo by Atlantic Ambience via Pexels.

Three signals will tell you more about where this actually goes than any headline claiming rescheduling is imminent or dead. First, watch the pending ALJ recommendation from the July 2026 hearing. If it comes back favorable to full rescheduling, the real test isn't the recommendation itself -- it's whether DOJ moves to finalize a broader rule despite the House spending-bill rider restricting funds for exactly that action. A favorable recommendation sitting unactioned because of a funding fight would be its own kind of answer.

Second, track state-by-state data on actual shelf prices from medical-only operators, not their earnings calls. Maryland is the test case worth watching first, given the concrete per-store savings estimates already floating around that market -- if high-volume Maryland medical retailers cut prices materially over the next year, that's meaningful evidence of pass-through. If their margins simply improve while shelf prices hold steady, that tells you competition in that particular market isn't strong enough to force pass-through, at least not yet.

Third, watch whether SAFE/SAFER Banking gets any renewed legislative momentum now that partial rescheduling is a reality on the ground. Historically, banking reform efforts have lagged behind scheduling reform by years rather than months in comparable regulatory sequences, and there's no strong reason yet to expect cannabis banking to break that pattern just because medical marijuana moved to Schedule III. If SAFE/SAFER stays stalled through 2027, that's consistent with the historical lag, not a surprise.

For skeptics, the fair counter-case deserves real weight: if full rescheduling stalls out in litigation, and the House spending-bill rider holds through appropriations, the medical/adult-use split created in April 2026 could persist indefinitely rather than resolving into full legalization on any predictable timeline. In that scenario, most consumers in adult-use-dominant states -- which is most cannabis consumers in the country -- never see a 280E-driven price effect at all, because the tier they're buying from was never included in the relief to begin with.

The more reasonable bet over this window: expect margin improvement and consolidation activity among medical operators well before you see any broad, visible retail price drop that can be credibly tied to rescheduling specifically. Consolidation tends to move faster than pass-through, because it only requires operator-level decisions rather than competitive market pressure.

Strip away the headline framing and what's left is a fairly narrow, mechanical story: a tax provision written in 1982 to punish drug traffickers no longer applies to a specific slice of the cannabis industry, and that slice's balance sheets are going to look better because of it. That's real money, and for the operators who qualify, it's a genuine structural improvement in how their businesses function financially. But it's a balance-sheet event long before it's ever a shelf-price event, and there is no rule, market force, or historical pattern that guarantees the gap between those two things closes quickly, or closes at all for a given operator.

The two-tier structure created by the April 2026 rule -- medical programs relieved of 280E, adult-use programs still fully exposed to it -- isn't a temporary implementation quirk. It's how the rule was written, and it means the benefit is unevenly distributed by design, not by accident. Anyone waiting for a broad, uniform cannabis price drop tied to rescheduling is waiting for something the rule was never structured to deliver.

If you want early, credible evidence of what this actually does to prices, watch state medical markets -- Maryland first, others as data accumulates -- rather than adult-use headlines or federal political theater. And keep an eye on the tax courts: the IRS's fight against retroactive 280E claims will directly shape how much of this relief operators actually get to bank versus how much gets litigated away. If retail prices do fall broadly across the country over the next few years, don't be surprised if oversupply and market saturation, already visible in the 2025 sales declines across 23 states, end up deserving far more credit for it than rescheduling ever does.